Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Significant Increase in Short Interest

Candel Therapeutics, Inc. (NASDAQ:CADL) saw a large increase in short interest in July. As of July 31st, there was short interest totalling 1,480,000 shares, an increase of 5.7% from the July 15th total of 1,400,000 shares. Approximately 8.0% of the company’s stock are sold short. Based on an average daily trading volume, of 650,800 shares, the short-interest ratio is currently 2.3 days.

Insider Buying and Selling at Candel Therapeutics

In related news, CEO Paul Peter Tak sold 20,293 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $5.97, for a total transaction of $121,149.21. Following the sale, the chief executive officer now directly owns 353,263 shares of the company’s stock, valued at $2,108,980.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CTO Seshu Tyagarajan sold 14,851 shares of the company’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $6.47, for a total value of $96,085.97. Following the completion of the transaction, the chief technology officer now owns 146,049 shares of the company’s stock, valued at approximately $944,937.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Paul Peter Tak sold 20,293 shares of Candel Therapeutics stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $5.97, for a total transaction of $121,149.21. Following the sale, the chief executive officer now owns 353,263 shares in the company, valued at approximately $2,108,980.11. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 89,783 shares of company stock worth $559,636. 41.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Candel Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC acquired a new position in shares of Candel Therapeutics in the 2nd quarter valued at $162,000. Rhumbline Advisers acquired a new position in Candel Therapeutics in the second quarter valued at approximately $143,000. Point72 DIFC Ltd purchased a new stake in Candel Therapeutics during the second quarter worth $31,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Candel Therapeutics during the 2nd quarter worth about $338,000. 13.93% of the stock is currently owned by institutional investors.

Candel Therapeutics Trading Up 0.6 %

Shares of NASDAQ:CADL traded up $0.03 on Tuesday, hitting $5.28. 11,303 shares of the company’s stock were exchanged, compared to its average volume of 2,411,401. Candel Therapeutics has a 12 month low of $0.66 and a 12 month high of $14.30. The business’s 50 day simple moving average is $6.12 and its two-hundred day simple moving average is $5.39. The stock has a market capitalization of $157.11 million, a price-to-earnings ratio of -4.10 and a beta of -0.95. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.00 and a quick ratio of 2.00.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.